Clinical Trials Browser

Phase 2 × Amyloidosis × Lenalidomide × Clear all

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Phase 2 Recruiting

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT01194791 2017-04-25

LENDEXAL

Phase 2 Completed

Immunoglobulin Light-chain Amyloidosis, Amyloidosis